Jane E. Kiernan

Independent Director at Axonics

Jane E. Kiernan has over 30 years of executive and management leadership in healthcare with both public and private companies. Kiernan joined the Axonics Modulation Technologies, Inc. Board of Directors on April 8, 2019 and serves on the Audit Committee. Kiernan is a cofounder of K2 Biotechnology Ventures, an organization engaged in developing and commercializing university and medical center innovations in partnership with venture capital, healthcare corporations and philanthropic healthcare foundation partners. From 2010–2017, Kiernan served as the CEO of Salter Labs, a manufacturer of specialty medical devices with approximately 1,000 employees and $85 million in annual revenue. From 2006–2011, Kiernan served on the Board of Directors and as Chair of the Audit Committee of Nasdaq-listed American Medical Systems (AMS) prior to AMS being acquired by Endo Pharmaceuticals (NASDAQ: ENDP) for $2.9 billion. From 2001–2010, Kiernan held executive and general management positions with profit and loss responsibility for as much as $1.5 billion in revenue with both Baxter Healthcare Corporation and Allegiance Healthcare Corporation. As a community leader, Kiernan serves on the Board of Directors for Ryan Banks Academy and has served on the Board of Directors of the American Red Cross of Greater Chicago. In addition, she is a past President of the Healthcare Businesswomen’s Association, Chicago Chapter. Kiernan holds a B.S. degree in business from Southern Methodist University.

Location

Chicago, United States

Links


Org chart

This person is not in the org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Axonics

2 followers

Axonics® is dedicated to improving the quality of life of people suffering from bladder and bowel dysfunction, conditions that impact the lives of tens of millions of adults globally. The Company’s products include the Axonics Sacral Neuromodulation System designed to treat overactive bladder and fecal incontinence and the Bulkamid® hydrogel designed to treat women with stress urinary incontinence.


Industries

Employees

201-500

Links